Countdown to West Pharmaceutical (WST) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS

Core Viewpoint - Wall Street analysts forecast a slight increase in West Pharmaceutical Services' quarterly earnings and revenues, indicating stable growth in the company's financial performance [1]. Earnings Estimates - Analysts predict quarterly earnings of $1.83 per share, reflecting a year-over-year increase of 0.6% [1]. - Revenue is anticipated to reach $794.26 million, showing a 6.1% increase compared to the same quarter last year [1]. - The consensus EPS estimate has remained unchanged over the past 30 days, indicating analysts' reassessment of their projections [2]. Key Metrics Projections - 'Net Sales- Contract-Manufactured Products' are expected to be $144.45 million, representing a 7.1% increase from the previous year [5]. - 'Net Sales- Proprietary Products' is projected at $648.56 million, indicating a 5.7% increase year-over-year [5]. - 'Change in Organic Revenue' is forecasted to be 1.8%, down from 3.3% in the previous year [5]. Profit Estimates - The estimated 'Gross Profit- Proprietary Products' is $257.16 million, compared to $250.70 million from the previous year [6]. - The consensus estimate for 'Gross Profit- Contract-Manufactured Products' stands at $25.76 million, up from $22.90 million year-over-year [6]. Market Performance - Shares of West Pharmaceutical have experienced a return of -8.8% over the past month, contrasting with the S&P 500 composite's unchanged performance [6]. - The company holds a Zacks Rank 2 (Buy), suggesting expectations of outperforming the overall market in the near future [6].